the aid library

LIST OPTIONS

Filter

3583

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19)
recommended

Organisation Mondiale de la Santé OMS (2021) C_WHO

‎‎Orientations provisoires, 28 janvier 2021 Dans cette version mise à jour des orientations sur la sécurité biologique en laboratoire en rapport avec le SARS-CoV-2, le virus responsable de la maladie à coronavirus 2019 (COVID-19), les points suivants ont été ajoutés : aspects de... more

Download (113)

View PDF (173)

Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19, 2 July 2021

World Health Organization WHO (2021) C_WHO

Countries across the world are facing diverse epidemiological situations with varying response capacities and access to life saving tools. The World Health Organization (WHO) recommends that national authorities continue to apply a risk-based approach when implementing measures related to COVID-19... more

Considérations politiques relatives à la mise en oeuvre d’une approche fondée sur les risques pour les voyages internationaux dans le cadre de la COVID-19, 2 juillet 2021

Organisation mondiale de la Santé OMS (2021) C_WHO

Les pays du monde entier sont confrontés à des situations épidémiologiques diverses, et disposent de capacités de réaction différentes et d’un accès inégal aux outils permettant de sauver des vies. L’Organisation mondiale de la Santé (OMS) recommande aux autorités nationales de contin... more

External Link

Mettre fin à la propagation du virus

Organisation Mondiale de la Santé OMS (2021) C_WHO

Lorsqu’un virus circule largement dans une population et entraîne de nombreuses infections, la probabilité de mutation augmente. Plus un virus a de possibilités de se propager, plus il se réplique – et plus il est susceptible de muter. L’arrêt de la propagation du virus à la source res... more

External Link

The successful COVID-19 vaccine rollout in Chile: Factors and challenges

Castillo C., Villalobos Dintrans P. et al (2021) C2

The aim of this article is to identify the elements behind the country’s successful COVID-19 rollout as well as lessons and chal lenges derived from this process. The analysis is relevant to many countries today—as they keep searching for strategies to cope with the second year of the COVID-19 p... more

Download (152)

View PDF (189)

Covid-19 Test to Treat Guidelines
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

n response to the outbreak, the Africa Centres for Disease Control and Prevention (Africa CDC) has been supporting African Union Member States in responding to the COVID-19 pandemic through a variety of interventions such as non-pharmaceutical interventions, quarantine, testing, isolation, contact t... more

External Link

The global distribution of lymphatic filariasis, 2000–2018: a geospatial analysis

The Lancet Global Health (2020) C1

Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA) of antihelmintics is recommended by WHO to elimina... more

ACT-Accelerator Prioritized Strategy & Budget for 2021

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2021) CC

In 2021 ACT-Accelerator will intensify its drive for equity and scale in the delivery of essential COVID-19 tools, while managing emerging viral risks. To address these major shifts and maintain momentum, ACT-Accelerator has defined four strategic priorities for 2021: Rapidly scale up the delivery o... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (8738)

View PDF (2683)

Guide Material for Medical Store Management Training
recommended

Community Development Medicinal Unit (2012) C_WHO

Drugs and medical supplies are dispensed at the cutting edge level of the interface between the public health system and the people. Availability or lack of it brings either credit or discredit to the public health system. The primary reason for holding stocks of medicines and medical supplies in a ... more

Download (246)

View PDF (348)

Trends and Inequalities in Young Child Nutrition in Rwanda: Further Analysis of the 2014-15 Demographic and Health Survey

Yourkavitch, Jennifer Rockville, Maryland, USA: ICF (2018) C2

DHS Further Analysis Reports No. 109 - This report documents trends in key child nutrition indicators in Rwanda. Data from the Demographic and Health Surveys (DHS) in 2005, 2010, and 2014-15 were analyzed, disaggregated by selected equity-related variables, and tested for trends. Over the survey per... more

Download (522)

View PDF (600)

A Comparison of Summary Measures of Quality of Service and Quality of Care for Family Planning in Haiti, Malawi, and Tanzania

Mallick, Lindsay, Wenjuan Wang, Temsah, Gheda (2017) C1

DHS Methodological Report No. 20

This study used Service Provision Assessment (SPA) and Demographic and Health Survey (DHS) data from Haiti, Malawi, and Tanzania to compare traditionally used additive methods with a data reduction method—principal component analysis (PCA).
We scored ... more

Download (336)

View PDF (357)

Vulnerability in Myanmar: A Secondary Data Review of Needs, Coverage and Gaps

Humanitarian Assistance and Resilience Programme Facility (HARP-F) & Myanmar Information Management Unit (MIMU) (2018) C1

Based on the Vulnerability Index developed in this review, an estimated 22.7 million persons in Myanmar, or 44% of the population, were found to have some form of vulnerability related to human development and/or exposure to active conflict/violence. These people experience varying combinations of p... more

Household transmission investigation protocol for 2019-novel coronavirus (2019-nCoV) infection
recommended

World Health Organization WHO (2020) C_WHO

The household transmission investigation is a case-ascertained prospective study of all identified household contacts of a laboratory confirmed 2019-nCoV infection (see 2.2 Study population). It is intended to provide rapid and early information on the clinical, epidemiological and virological chara... more

Manejo de urgencias del COVID-19 Documento técnico

Centro de Coordinación de Alertasy Emergencias Sanitarias Ministerio de sanidad - España (2020) C1

El 31 de diciembrede 2019 las Autoridades de la República Popular China, comunicaron a la OMS varios casos de neumonía de etiología desconocida en Wuhan, una ciudad situada en la provincia china de Hubei. Una semana más tarde confirmaron que se trataba de un nuevo co... more

Download (142)

View PDF (145)

Fontes e distribuição de oxigênio para os centros de tratamento da COVID-19

Pan American Health Organization PAHO, World Health Organization WHO (2020) C_WHO

COVID-19 e oxigênio: Os dados da China sugerem que embora a maioria das pessoas com COVID-19 tenham doença leve (40%) ou moderada (40%), cerca de 15% apresentam doença grave que requer oxigenoterapia, e 5% ficam em estado crítico e precisam de tratamento em uma unidade de terapia intensiva. Alé... more

Medical PPE production in Africa: Promoting Local Manufacturers to support the COVID-19 Response (Workshop report)

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C1

The global pandemic has highlighted fragility in international supply chains and the dependency of many African countries on imported personal protective equipment (PPE). Market pressures have also increased prices for imported supplies and put additional pressure on areas with limited resources for... more

External Link

Effect of COVID-19 pandemic on provision of sexual and reproductive health services in primary health facilities in Nigeria: a cross-sectional study

Adelekan, B.; E. Goldson, Z. Abubakar et al. Repoductive Health Journal (2021) CC

RESULTS: Between 76 and 97% of the PHCS offered RMCAH services before the lockdown. Except in antenatal, delivery and adolescent care, there was a decline of between 2 and 6% in all the services during the lockdown and up to 10% decline after the lockdown with variation across and within States. Dur... more

External Link

Modelling historical changes in the force-of-infection of Chagas disease to inform control and elimination programmes: application in Colombia

Cucunubá, Z.; Nouvellet, P.; Conteh, L. et al. BMJ Global Health (2022) CC

BMJ Glob Health 2017;2:e000345. doi:10.1136/bmjgh-2017-000345. WHO's 2020 milestones for Chagas disease include having all endemic Latin American countries certified with no intradomiciliary Trypanosoma cruzi transmission, and infected patients under care. Evaluating the variation in historical expo... more

External Link

Guide posts for investment in primary health care and projected resource needs in 67 low-income and middle-income countries: a modelling study

Stenberg, K.; O. Hanssen; M. Bertram et al. Lancet Glob Health (2019) C1

Background: Primary health care (PHC) is a driving force for advancing towards universal health coverage (UHC). PHC-oriented health systems bring enormous benefits but require substantial financial investments. Here, we aim to present measures for PHC investments and project the associated resource ... more

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19) recommended

Covid-19 Test to Treat Guidelines recommended

Guide Material for Medical Store Management Training recommended

Household transmission investigation protocol for 2019-novel coronavirus (2019-nCoV) infection recommended

Orientations sur la sécurité biologique en laboratoire en rapport avec la maladie à coronavirus 2019 (‎‎COVID-19)
recommended

Covid-19 Test to Treat Guidelines
recommended

Guide Material for Medical Store Management Training
recommended

Household transmission investigation protocol for 2019-novel coronavirus (2019-nCoV) infection
recommended